[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Lewis et al., 1977 - Google Patents

Coagulopathies

Lewis et al., 1977

Document ID
13761174628025713996
Author
Lewis J
Spero J
Hasiba U
Publication year
Publication venue
Disease-A-Month

External Links

Snippet

BLEEDING TIME: In vivo test involving a cut or puncture of the skin under constant conditions; sensitive to decreased platelet number, abnormal platelet function and increased capillary fragility. BRADYKININ: A vasoactive peptide made available by the action of the …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Similar Documents

Publication Publication Date Title
Handin et al. Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome
Larrieu et al. Congenital bleeding disorders with long bleeding time and normal platelet count: II. Von Willebrand's disease (report of thirty-seven patients)
Al-Mondhiry et al. Fibrinogen"" New York"--an abnormal fibrinogen associated with thromboembolism: functional evaluation
Saba et al. Type IIB Tampa: a variant of von Willebrand disease with chronic thrombocytopenia, circulating platelet aggregates, and spontaneous platelet aggregation
Rapaport et al. The blood clotting properties of rabbit peritoneal leukocytes in vitro
Hoyer Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors)
Poon et al. Evidence that functional subunits of antihemophilic factor (Factor VIII) are linked by noncovalent bonds
Parkin et al. A further inherited variant of coagulation factor X
Ockelford et al. Disseminated intravascular coagulation: The application and utility of diagnostic tests
LANE et al. Factor V antibody and disseminated intravascular coagulation
Lewis et al. Coagulopathies
Peuscher et al. Acquired, transient factor X (Stuart Factor) deficiency in a patient with mycoplasma pneumonial infection
Davis et al. Circulating inhibitors of blood coagulation associated with procainamide‐induced lupus erythematosus
Conley et al. Studies on the initiation of blood coagulation. II. An anticoagulant inhibiting the activation of a plasma thromboplastic factor
Lankiewicz et al. A unique circulating inhibitor with specificity for coagulation factor X
Åkerblom et al. Freezing technique and quality of fresh-frozen plasma
Burnouf et al. Protein composition and activation markers in plasma collected by three apheresis procedures
Soliman et al. Coagulation defects
Hellstern Composition of plasma
Harbaugh et al. Antithrombin and antithromboplastin activity accompanying IgG myeloma: Report of a case with a severe bleeding tendency
Kraiem et al. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs
Lian et al. In vivo dissociation of factor vii (ahf) activity and factor viii‐related antigen in von willebrand's disease
Mammen et al. Hypercoagulable states
Lewis et al. 7 Transfusion Support for Congenital Clotting Deficiencies Other than Haemophilia
Phillips et al. Effects of puff adder venom on the coagulation mechanism